Suppr超能文献

Shp2和Pten在骨髓增殖中具有拮抗作用,但在哺乳动物中协同促进红细胞生成。

Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals.

作者信息

Zhu Helen He, Luo Xiaolin, Zhang Kaiqing, Cui Jian, Zhao Huifang, Ji Zhongzhong, Zhou Zhicheng, Yao Jufang, Zeng Lifan, Ji Kaihong, Gao Wei-Qiang, Zhang Zhong-Yin, Feng Gen-Sheng

机构信息

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China; Department of Pathology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093-0864;

Department of Pathology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093-0864;

出版信息

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13342-7. doi: 10.1073/pnas.1507599112. Epub 2015 Oct 12.

Abstract

Previous data suggested a negative role of phosphatase and tensin homolog (Pten) and a positive function of SH2-containing tyrosine phosphatase (Shp2)/Ptpn11 in myelopoiesis and leukemogenesis. Herein we demonstrate that ablating Shp2 indeed suppressed the myeloproliferative effect of Pten loss, indicating directly opposing functions between pathways regulated by these two enzymes. Surprisingly, the Shp2 and Pten double-knockout mice suffered lethal anemia, a phenotype that reveals previously unappreciated cooperative roles of Pten and Shp2 in erythropoiesis. The lethal anemia was caused collectively by skewed progenitor differentiation and shortened erythrocyte lifespan. Consistently, treatment of Pten-deficient mice with a specific Shp2 inhibitor suppressed myeloproliferative neoplasm while causing anemia. These results identify concerted actions of Pten and Shp2 in promoting erythropoiesis, while acting antagonistically in myeloproliferative neoplasm development. This study illustrates cell type-specific signal cross-talk in blood cell lineages, and will guide better design of pharmaceuticals for leukemia and other types of cancer in the era of precision medicine.

摘要

先前的数据表明,磷酸酶和张力蛋白同源物(Pten)具有负面作用,而含SH2结构域的酪氨酸磷酸酶(Shp2)/Ptpn11在骨髓生成和白血病发生中具有正面功能。在此,我们证明敲除Shp2确实抑制了Pten缺失的骨髓增殖效应,表明这两种酶调控的信号通路具有直接相反的功能。令人惊讶的是,Shp2和Pten双敲除小鼠患致死性贫血,这一表型揭示了Pten和Shp2在红细胞生成中此前未被认识到的协同作用。致死性贫血是由祖细胞分化异常和红细胞寿命缩短共同导致的。同样,用特异性Shp2抑制剂治疗Pten缺陷小鼠可抑制骨髓增殖性肿瘤,但会导致贫血。这些结果表明Pten和Shp2在促进红细胞生成中协同作用,而在骨髓增殖性肿瘤发展中起拮抗作用。本研究阐明了血细胞谱系中细胞类型特异性的信号串扰,并将指导精准医学时代白血病和其他类型癌症药物的更好设计。

相似文献

1
Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals.
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13342-7. doi: 10.1073/pnas.1507599112. Epub 2015 Oct 12.
2
Treating leukemia at the risk of inducing severe anemia.
Exp Hematol. 2016 May;44(5):329-31. doi: 10.1016/j.exphem.2016.01.004. Epub 2016 Jan 27.
4
Loss of PTEN causes SHP2 activation, making lung cancer cells unresponsive to IFN-γ.
Biochem Biophys Res Commun. 2015 Oct 23;466(3):578-84. doi: 10.1016/j.bbrc.2015.09.085. Epub 2015 Sep 16.
5
Role of SHP2 in hematopoiesis and leukemogenesis.
Curr Opin Hematol. 2017 Jul;24(4):307-313. doi: 10.1097/MOH.0000000000000345.
6
Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer.
Immunobiology. 2012 Sep;217(9):926-34. doi: 10.1016/j.imbio.2012.01.001. Epub 2012 Jan 4.
7
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase.
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E79-88. doi: 10.1073/pnas.1213000110. Epub 2012 Dec 10.
8
Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.
Front Med. 2012 Sep;6(3):275-9. doi: 10.1007/s11684-012-0216-4. Epub 2012 Aug 6.
9
Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13156-13161. doi: 10.1073/pnas.1604450113. Epub 2016 Oct 31.

引用本文的文献

1
Complex Roles of /SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy.
Annu Rev Cancer Biol. 2024 Jun;8(1):15-33. doi: 10.1146/annurev-cancerbio-062722-013740. Epub 2023 Dec 6.
2
Concurrent Disruption of the Ras/MAPK and NF-κB Pathways Induces Circadian Deregulation and Hepatocarcinogenesis.
Mol Cancer Res. 2022 Mar 1;20(3):337-349. doi: 10.1158/1541-7786.MCR-21-0479.
3
Molecular pathogenesis of the myeloproliferative neoplasms.
J Hematol Oncol. 2021 Jun 30;14(1):103. doi: 10.1186/s13045-021-01116-z.
5
Tumor immunology and immunotherapy: a journey I started from Hangzhou.
J Zhejiang Univ Sci B. 2019 May;20(5):373-380. doi: 10.1631/jzus.B1900204.
6
Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
J Hepatol. 2018 Jul;69(1):79-88. doi: 10.1016/j.jhep.2018.02.014. Epub 2018 Mar 2.
7
β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Hepatology. 2018 May;67(5):1807-1822. doi: 10.1002/hep.29661. Epub 2018 Apr 6.
8
Role of SHP2 in hematopoiesis and leukemogenesis.
Curr Opin Hematol. 2017 Jul;24(4):307-313. doi: 10.1097/MOH.0000000000000345.
10
Treating leukemia at the risk of inducing severe anemia.
Exp Hematol. 2016 May;44(5):329-31. doi: 10.1016/j.exphem.2016.01.004. Epub 2016 Jan 27.

本文引用的文献

1
Therapeutic potential of targeting the oncogenic SHP2 phosphatase.
J Med Chem. 2014 Aug 14;57(15):6594-609. doi: 10.1021/jm5006176. Epub 2014 Jul 28.
2
Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.
4
5
The functions and regulation of the PTEN tumour suppressor.
Nat Rev Mol Cell Biol. 2012 Apr 4;13(5):283-96. doi: 10.1038/nrm3330.
6
7
Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool.
Blood. 2011 May 19;117(20):5350-61. doi: 10.1182/blood-2011-01-333476. Epub 2011 Mar 30.
8
PTEN loss in the continuum of common cancers, rare syndromes and mouse models.
Nat Rev Cancer. 2011 Apr;11(4):289-301. doi: 10.1038/nrc3037.
9
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.
Blood. 2011 Apr 21;117(16):4253-61. doi: 10.1182/blood-2010-11-319517. Epub 2011 Feb 25.
10
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Blood. 2009 Jul 16;114(3):647-50. doi: 10.1182/blood-2009-02-206722. Epub 2009 May 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验